Lung Cancer News and Research

Latest Lung Cancer News and Research

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Winter months presents a good opportunity to test our homes for radon

Keeping our homes more tightly closed during the winter months allows indoor air pollutants to build up in higher concentrations. It presents a good opportunity to test our homes for radon, a colourless, odourless gas that is produced from the natural breakdown of uranium in rocks and soil.

9 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

MUHC unveils new Lung Cancer Navigation Program

A diagnosis of lung cancer can come as a hard blow. The disease has one of the highest mortality rates of all cancers and the sheer complexity of therapy - often involving radiation, chemotherapy and surgery - can leave patients feeling confused and isolated. To help these patients navigate through the complicated treatment process and medical appointments, the MUHC has unveiled its new Lung Cancer Navigation Program (LCNP).

8 Jan 2010

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

As Congress negotiates a final health care reform bill, lawmakers should seize this unprecedented opportunity to invest in proven measures that prevent costly diseases from occurring in the first place, which will improve health and reduce health care costs. These include measures to prevent and reduce tobacco use, which remains the leading cause of preventable death in the United States, killing more than 400,000 people and costing the nation $96 billion in health care expenditures annually.

8 Jan 2010

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

New study reveals high-silica coal causes lung cancer

The volcanic eruptions thought responsible for Earth's largest mass extinction - which killed more than 70 percent of plants and animals 250 million years ago - is still taking lives today. That's the conclusion of a new study showing, for the first time, that the high silica content of coal in one region of China may be interacting with volatile substances in the coal to cause unusually high rates of lung cancer.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

'Make Today the Day' public awareness campaign to quit smoking launched

At a time when many smokers consider quitting for the New Year, today is a timely launch of a partnership that joins together mutual public health interests sought by the American Lung Association in California, Healthy San Francisco and the city's Public Health Office in a citywide public awareness campaign aimed to help smokers achieve that goal.

6 Jan 2010

Radiologists use new interventional NanoKnife technique to treat lung cancer

Interventional radiologists at BAPTIST HEALTH Medical Center - Little Rock recently became the first physicians in the U.S. to use a new image-guided interventional NanoKnife technique to treat a malignant nodule within the lung.

6 Jan 2010

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate

BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

6 Jan 2010

MindUp Cancer Project integrated into HIRU

Hiru Corporation welcomes the integration of its MindUp Cancer Project into the HIRU corporation. This asset was recently acquired on a cash and stock basis as reported previously.

5 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

RFA reduces pain in bone metastases patients

Image-guided radiofrequency ablation (RFA), a minimally invasive cancer treatment which can be performed in the outpatient setting, significantly reduced the level of pain experienced by cancer patients with bone (osseous) metastases, limiting the need for strong narcotic pain management, and supporting improved patient frame of mind, according to results of an American College of Radiology Imaging Network (ACRIN) study published online in the journal Cancer.

5 Jan 2010

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Winter months presents a good opportunity to test our homes for radon

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

MUHC unveils new Lung Cancer Navigation Program

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

New study reveals high-silica coal causes lung cancer

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

'Make Today the Day' public awareness campaign to quit smoking launched

Radiologists use new interventional NanoKnife technique to treat lung cancer

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate

MindUp Cancer Project integrated into HIRU

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

RFA reduces pain in bone metastases patients

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in